Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

Shi, Yuankai; He, Xiaohong; Yang, Shih-Chieh; Ai, Bin; Zhang, Changgong; Huang, Ding-Zhi; Dong, Mei; Liu, Peng; Zhou, Shengyu; Han, Xiaohong

doi:10.1159/000098418

Cited by 34 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ramosetron administered alone was as effective as granisetron or ondansetron for CINV prevention in clinical trials [10][11][12]. In combination with dexamethasone, ramosetron showed a 77% CR rate in acute period, which is comparable to that of granisetron (82%) [16].…”

Section: Discussionmentioning

confidence: 89%

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21

et al. 2015

View full text Add to dashboard Cite

Background. A combination of serotonin receptor (5-hydroxytryptamine receptor type 3) antagonists, NK-1 receptor antagonist, and steroid improves the complete response (CR) of chemotherapy-induced nausea and vomiting (CINV) in cancer patients. Ramosetron's efficacy in this triple combination regimen has not been investigated.This prospective, multicenter, single-blind,randomized,phaseIIIstudycompares a combination of ramosetron, aprepitant, and dexamethasone (RAD) with a combination of ondansetron, aprepitant, and dexamethasone (OAD) to prove the noninferiority of RAD in controlling highly emetogenic CINV. Methods. Aprepitant and dexamethasone were orally administered for both arms. Ramosetron and ondansetron were intravenouslygiventothe RADandOADgroups.Theprimaryendpoint was no vomiting and retching and no need for rescue medication duringtheacuteperiod(day1);thenoninferioritymarginwas215%.

show abstract

Section: Discussionmentioning

confidence: 89%

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Ramosetron is a potent 5-HT3 receptor antagonist that is effective in relieving chemotherapy-induced nausea and vomiting, and is currently being developed for IBS-D [52,53] . Preliminary pharmacokinetic data suggest that it has a greater affinity, slower dissociation, and stronger antagonism at the 5-HT3 receptor than either alosetron or cilansetron [54] .…”

Section: -Ht3 Antagonistsmentioning

confidence: 99%

Updates on treatment of irritable bowel syndrome

Hammerle¹,

Surawicz²

2008

WJG

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder characterized by abdominal pain and discomfort in association with altered bowel habits. It is estimated to affect 10%-15% of the Western population, and has a large impact on quality of life and (in)direct healthcare costs. IBS is a multifactorial disorder involving dysregulation within the brain-gut axis, and it is frequently associated with gastrointestinal motor and sensory dysfunction, enteric and central nervous system irregularities, neuroimmune dysregulation, and postinfectious inflammation. As with other functional medical disorders, the treatment for IBS can be challenging. Conventional therapy for those with moderate to severe symptoms is largely unsatisfactory, and the development of new and effective drugs is made difficult by the complex pathogenesis, variety of symptoms, and lack of objective clinical findings that are the hallmark of this disorder. Fortunately, research advances over the past several decades have provided insight into potential mechanisms responsible for the pathogenesis of IBS, and have led to the development of several promising pharmaceutical agents. In recent years there has been much publicity over several of these new IBS medications (alosetron and tegaserod) because of their reported association with ischemic colitis and cardiovascular disease. While these agents remain available for use under restricted prescribing programs, this highlights the need for continued development of safe and effective medication for IBS. This article provides a physiologicallybased overview of recently developed and frequently employed pharmaceutical agents used to treat IBS, and discusses some non-pharmaceutical options that may be beneficial in this disorder.

show abstract

“…Ramosetron, a new 5-HT 3 receptor antagonist, has higher potency and prolonged activity than previously developed 5-HT 3 antagonists as an antiemetic after chemotherapy [19,20] or surgery [21][22][23]. To the best of our knowledge, no reports have compared the efficacy of ramosetron with that of ondansetron for preventing PONV after LC.…”

Section: Introductionmentioning

confidence: 99%

Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy

Ryu

Hwang

et al. 2009

Surg Endosc

View full text Add to dashboard Cite

show abstract

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

Cited by 34 publications

References 20 publications

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21

Updates on treatment of irritable bowel syndrome

Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy

Contact Info

Product

Resources

About